Overview

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
0
Participant gender:
All
Summary
This study mainly evaluate the clinical effect of Apatinib in the treatment of patients with pulmonary metastasis of hepatocellular carcinoma.Half of participants will receive Apatinib and transcatheter arterial chemoembolization (TACE) therapy in combination,while the other half will receive TACE therapy alone.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborators:
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Zhejiang University
Ningbo No.2 Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
The Central Hospital of Lishui City
Treatments:
Apatinib
Chlorotrianisene
Criteria
Inclusion Criteria:

- clinical diagnosis of hepatocellular carcinoma

- refused to sorafenib treatment

- have at least one measurable pulmonary lesions

- expected survival time ≥ 12 weeks

Exclusion Criteria:

- within four weeks before the study received radiotherapy or chemotherapy

- With a variety of factors influencing oral drugs taking and absorption (such as unable
to swallow, chronic diarrhea and intestinal obstruction)